THE ROLLING STONES ADD ADDITIONAL TOUR DATE IN MISSOURI FOR THE STONES TOUR ‘24 HACKNEY DIAMONDS
Today, The Rolling Stones have announced they will be extending the STONES TOUR ’24 HACKNEY DIAMONDS with an additional stop in Ridgedale, Missouri, on July 21 at Thunder Ridge Nature Arena. Tickets are on sale Friday, May 31, 2024, at 10 a.m. local time. For ticketing information, please visit www.rollingstones.com.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523672007/en/
(Graphic: Business Wire)
Mick, Keith and Ronnie kicked off their wildly anticipated tour in Houston, Texas, last month and have brought their legendary show to cities across the United States, including the New Orleans Jazz and Heritage Festival, treating fans to their iconic hits and new music from their critically acclaimed new album HACKNEY DIAMONDS. The STONES TOUR ‘24 HACKNEY DIAMONDS will make stops in 12 more cities across the U.S. and Canada with stops in East Rutherford, Foxboro, Orlando, Atlanta, Philadelphia, Cleveland, Denver, Chicago, Vancouver, Los Angeles and Santa Clara with a final stop in Ridgedale. Full tour routing is below.
Hackney Diamonds is their first studio set of new material since 2005’s A Bigger Bang. Since then, the Stones have continued to smash box office records on a series of global sell-out tours and released 2016’s GRAMMY® Award winning Blue & Lonesome, which featured their brilliant versions of many of the blues tracks that helped shape their sound and topped album charts around the world. In 2022, they thrilled European audiences totaling nearly a quarter of a million on the anniversary Sixty tour. The Rolling Stones have sold over 250 million albums worldwide.
Thunder Ridge Nature Arena — a decade in planning, development and construction with the ambition to create America’s most beautiful outdoor amphitheater — is scheduled to open this May as a one-of-a-kind immersive outdoor “musical postcard from Mother Nature.” Located in Ridgedale, Missouri, just a few miles from Branson, Thunder Ridge Nature Arena is described by its creator and visionary — noted conservationist and Bass Pro Shops founder Johnny Morris as a “gift of the Ozarks to the world.” It is the only venue on Earth completely dedicated to conservation.
AEG Presents’ Concerts West is the promoter of the Stones Tour ’24 Hackney Diamonds. For tickets and information, head to www.rollingstones.com.
THE ROLLING STONES – STONES TOUR ‘24 HACKNEY DIAMONDS
Sponsored by AARP
Thursday, May 23, 2024 | MetLife Stadium | East Rutherford, NJ |
Sunday, May 26, 2024 | MetLife Stadium | East Rutherford, NJ |
Thursday, May 30, 2024 | Gillette Stadium | Foxboro, MA |
Monday, June 3, 2024 | Camping World Stadium | Orlando, FL |
Friday, June 7, 2024 | Mercedes-Benz Stadium | Atlanta, GA |
Tuesday, June 11, 2024 | Lincoln Financial Field | Philadelphia, PA |
Saturday, June 15, 2024 | Cleveland Browns Stadium | Cleveland, OH |
Thursday, June 20, 2024 | Empower Field at Mile High | Denver, CO |
Thursday, June 27, 2024 | Soldier Field | Chicago, IL |
Sunday, June 30, 2024 | Soldier Field | Chicago, IL |
Friday, July 5, 2024 | BC Place | Vancouver, BC |
Wednesday, July 10, 2024 | SoFi Stadium | Los Angeles, CA |
Saturday, July 13, 2024 | SoFi Stadium | Los Angeles, CA |
Wednesday, July 17, 2024 | Levi’s® Stadium | Santa Clara, CA |
Sunday, July 21, 2024 | Thunder Ridge Nature Arena | Ridgedale, MO |
www.youtube.com/user/therollingstones
www.instagram.com/therollingstones
www.tiktok.com/@therollingstones
www.facebook.com/therollingstones
www.twitter.com/rollingstones
www.aegpresents.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523672007/en/
Contact information
The Rolling Stones Press Contacts:
Jessica Sciacchitano, jessica.sciacchitano@rcpmk.com
Amal Mokhtar, amal.mokhtar@rcpmk.com
Thunder Ridge Nature Arena Press Contact:
Jim Yeager, jim@breakwhitelight.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 13:00:00 CET | Press Release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom